Clearbridge Investments LLC sold over 3.2 million shares of
DexCom, Inc. (NASDAQ:DXCM), although they retain a $3.73 million stake within the company. The investment firm
PNC Financial Services Group Inc. and
King Luther Capital Management Corp increased their Dexcom holdings, whereas insiders such as Dexcom executives Matthew Dolan and Kevin Sayer sold shares. Dexcom had a steady performance, posting solid preliminary Q4 and 2020 revenues, recording significant growth, and outperforming other medical stocks this year. Notably, Dexcom reported strong Q1 2024 performance, beating analyst revenue forecasts. DexCom's Stelo Glucose Biosensor received FDA approval, expanding its product offerings. The company's
Direct-to-Watch feature is also expected to boost its G7 System. Dexcom's stocks have had fluctuations but the company had significant rebounds. The outlook remains optimistic, with Wall Street bulls backing the stock. However, the stock was undercut due to raised but light guidance, resulting in investor skepticism. Despite this, DexCom's Q1 Earnings beat estimates and volumes remain strong.
Dexcom DXCM News Analytics from Thu, 26 Oct 2023 07:00:00 GMT to Sun, 26 May 2024 15:12:30 GMT -
Rating 7
- Innovation 6
- Information 9
- Rumor 2
